Literature DB >> 16002679

Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro.

Pierpaolo Correale1, Maria Grazia Cusi, Maria Teresa Del Vecchio, Angelo Aquino, Salvatore Pasquale Prete, Salvatore Prete, Kwong Y Tsang, Lucia Micheli, Cristina Nencini, Marco La Placa, Francesco Montagnani, Chiara Terrosi, Michele Caraglia, Vincenzo Formica, Giorgio Giorgi, Enzo Bonmassar, Guido Francini.   

Abstract

Gemcitabine, oxaliplatin, leucovorin, and 5-fluorouracil (GOLF) is a novel multidrug regimen inducing high levels of necrosis and apoptosis in colon carcinoma cells. This regimen is also able to promote a process of Ag remodeling including up-regulation of immunotherapy targets like carcinoembryonic Ag (CEA), thymidylate synthase (TS). We have conducted a preclinical study aimed to investigate whether these drug-induced modifications would also enhance colon cancer cell immunogenicity. Several CTL lines were thus generated by in vitro stimulating human HLA-A(*)02.01(+) PBMCs, from normal donors and colon cancer patients, with autologous dendritic cells cross-primed with cell lysates of colon cancer cells untreated, irradiated, or previously exposed to different drug treatments including the GOLF regimen. Class I HLA-restricted cytolytic activity of these CTL lines was tested against colon cancer cells and CEA and TS gene transfected target cells. These experiments revealed that CTLs sensitized with GOLF-treated cancer cells were much more effective than those sensitized with the untreated colon carcinoma cells or those exposed to the other treatments. CTL lines sensitized against the GOLF-treated colon cancer cells, also expressed a greater percentage of T-lymphocyte precursors able to recognize TS- and CEA-derived peptides. These results suggest that GOLF regimen is a powerful antitumor and immunomodulating regimen that can make the tumor cells a suitable means to induce an Ag-specific CTL response. These results suggest that a rationale combination of GOLF chemotherapy with cytokine-based immunotherapy could generate a chemotherapy-modulated Ag-specific T-lymphocyte response in cancer patients able to destroy the residual disease survived to the cytotoxic drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16002679     DOI: 10.4049/jimmunol.175.2.820

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice.

Authors:  Lukas W Pfannenstiel; Samuel S K Lam; Leisha A Emens; Elizabeth M Jaffee; Todd D Armstrong
Journal:  Cell Immunol       Date:  2010-03-06       Impact factor: 4.868

Review 2.  Immunological off-target effects of standard treatments in gastrointestinal cancers.

Authors:  A G Duffy; T F Greten
Journal:  Ann Oncol       Date:  2013-11-07       Impact factor: 32.976

3.  Identification of novel HLA-A*0201-restricted epitopes from anterior gradient-2 as a tumor-associated antigen against colorectal cancer.

Authors:  Hyun Ju Lee; Cheol Yi Hong; Chun-Ji Jin; Mi-Hyun Kim; Youn-Kyung Lee; Thanh-Nhan Nguyen-Pham; Hyunah Lee; Byoung Chul Park; Ik-Joo Chung; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Cell Mol Immunol       Date:  2012-01-09       Impact factor: 11.530

4.  Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination.

Authors:  Tae Heung Kang; Jin Hyup Lee; Chung Kil Song; Hee Dong Han; Byung Cheol Shin; Sara I Pai; Chien-Fu Hung; Cornelia Trimble; Jong-Seok Lim; Tae Woo Kim; T-C Wu
Journal:  Cancer Res       Date:  2007-01-15       Impact factor: 12.701

5.  Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model.

Authors:  C Bauer; F Bauernfeind; A Sterzik; M Orban; M Schnurr; H A Lehr; S Endres; A Eigler; M Dauer
Journal:  Gut       Date:  2007-03-29       Impact factor: 23.059

6.  Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients.

Authors:  Pierpaolo Correale; Cirino Botta; Elodia Claudio Martino; Cristina Ulivieri; Giuseppe Battaglia; Tommaso Carfagno; Maria Grazia Rossetti; Antonella Fioravanti; Giacomo Maria Guidelli; Sara Cheleschi; Claudia Gandolfo; Francesco Carbone; Tatiana Cosima Baldari; Pierfrancesco Tassone; Pierosandro Tagliaferri; Luigi Pirtoli; Maria Grazia Cusi
Journal:  Oncoimmunology       Date:  2015-12-21       Impact factor: 8.110

Review 7.  Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.

Authors:  L Bracci; G Schiavoni; A Sistigu; F Belardelli
Journal:  Cell Death Differ       Date:  2013-06-21       Impact factor: 15.828

Review 8.  Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization.

Authors:  Nikos G Gavalas; Alexandra Karadimou; Meletios A Dimopoulos; Aristotelis Bamias
Journal:  Clin Dev Immunol       Date:  2011-01-24

Review 9.  Current immunotherapeutic approaches in pancreatic cancer.

Authors:  Shigeo Koido; Sadamu Homma; Akitaka Takahara; Yoshihisa Namiki; Shintaro Tsukinaga; Jimi Mitobe; Shunichi Odahara; Toyokazu Yukawa; Hiroshi Matsudaira; Keisuke Nagatsuma; Kan Uchiyama; Kenichi Satoh; Masaki Ito; Hideo Komita; Hiroshi Arakawa; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  Clin Dev Immunol       Date:  2011-09-14

10.  Chitosan hydrogel containing GMCSF and a cancer drug exerts synergistic anti-tumor effects via the induction of CD8+ T cell-mediated anti-tumor immunity.

Authors:  Soo Hong Seo; Hee Dong Han; Kyung Hee Noh; Tae Woo Kim; Sang Wook Son
Journal:  Clin Exp Metastasis       Date:  2008-12-14       Impact factor: 4.510

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.